New Zealand markets close in 1 hour 18 minutes
  • NZX 50

    12,038.80
    +2.75 (+0.02%)
     
  • NZD/USD

    0.6496
    +0.0000 (+0.01%)
     
  • NZD/EUR

    0.5973
    +0.0002 (+0.04%)
     
  • ALL ORDS

    7,709.00
    -0.50 (-0.01%)
     
  • ASX 200

    7,489.50
    -4.30 (-0.06%)
     
  • OIL

    79.91
    +0.23 (+0.29%)
     
  • GOLD

    1,942.00
    -3.60 (-0.19%)
     
  • NASDAQ

    12,166.60
    +115.10 (+0.96%)
     
  • FTSE

    7,765.15
    +4.04 (+0.05%)
     
  • Dow Jones

    33,978.08
    +28.68 (+0.08%)
     
  • DAX

    15,150.03
    +17.23 (+0.11%)
     
  • Hang Seng

    22,552.56
    -136.34 (-0.60%)
     
  • NIKKEI 225

    27,470.46
    +87.90 (+0.32%)
     
  • NZD/JPY

    84.4640
    +0.1420 (+0.17%)
     

Why 2023 Could Be a Big Year for Biogen

Why 2023 Could Be a Big Year for Biogen

Biogen (NASDAQ: BIIB) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales. With the company's sales declining in recent years, Biogen needs a catalyst to turn things around and help inject some bullishness behind the business, and having an effective treatment for Alzheimer's could play a huge role in that objective. Next year could prove to be a pivotal one for Biogen as investors can finally get some much-needed answers about whether lecanemab, a promising Alzheimer's treatment, could be the game changer the healthcare company is hoping that it will be for the business.